Enhui Li
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Enhui Li has a total of 49 co-authors. Here are the top co-authors by number of shared publications:
Linlin Zhang
Department of Nephrology, Nanyang Central Hospital, Nanyang, Henan, China
2 shared publicationsWeiwei Zhang
Department of Nephrology, Xiangya Hospital, Central South University, Changsha, Hunan, China
2 shared publications- Xiangcheng Xiao
Department of Nephrology, Xiangya Hospital, Central South University, Changsha, China
2 shared publications Yikai He
Department of Nephrology and Rheumatology, First Hospital of Changsha, Changsha, Hunan, China
2 shared publicationsYizi Gong
Department of Nephrology, Xiangya Hospital, Central South University, Changsha, Hunan, China
2 shared publications- Ben Liu
Department of Urology, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China
1 shared publication
Latest Publications
- Open Access
- 1 January 2025
- Published by Wiley in International Journal of Nephrology
- Vol. 2025 (1) , 8899604
Continuous Renal Replacement Therapy Versus Intermittent Hemodialysis for Renal Prognosis in Elderly Patients With Acute Kidney Injury
Background: Continuous renal replacement therapy (CRRT) and intermittent hemodialysis (IHD) represent two common modes of renal replacement therapy (RRT) for elderly patients with acute kidney injury (AKI), but their clinical effectiveness is debated. This study aimed to compare the impact of CRRT and IHD on renal prognosis in elderly patients with AKI by analyzing their clinical data. Methods: The retrospective study population included elderly patients admitted to Xiangya Hospital between 2018 and 2022, who required RRT for AKI. Patients were separated into two cohorts based on the original RRT modes (CRRT or IHD). In our study, the primary outcome was recovery of renal function at discharge and the secondary outcome was RRT dependency rate at 90 days. A multivariate logistic regression model was constructed for the purpose of comparing the impact of CRRT and IHD on renal prognosis. Results: The mortality rate at the time of patient discharge was significantly elevated in the CRRT cohort relative to the IHD cohort (49.6% vs. 2.1%, p < 0.001). However, for the 155 patients who survived at discharge, the analysis revealed no statistically significant discrepancy in renal recovery across the two groups (40.3% vs. 59.7%, p = 0.694). Multivariate logistic regression analysis showed no statistically meaningful distinction among the CRRT and IHD groups concerning renal function recovery at discharge. Nevertheless, in comparison with IHD, CRRT reduced the risk of RRT dependence at 90 days. Conclusions: Our study indicated that CRRT and IHD have comparable effects on renal recovery at discharge in elderly patients with AKI who require RRT. However, in comparison with IHD, CRRT was linked to a diminished likelihood of requiring RRT at 90 days.
- 1 January 2025
- Published by Wiley in International Journal of Nephrology
- Vol. 2025 (1) , 8899604
Open AccessContinuous Renal Replacement Therapy Versus Intermittent Hemodialysis for Renal Prognosis in Elderly Patients With Acute Kidney Injury
Background: Continuous renal replacement therapy (CRRT) and intermittent hemodialysis (IHD) represent two common modes of renal replacement therapy (RRT) for elderly patients with acute kidney injury (AKI), but their clinical effectiveness is debated. This study aimed to compare the impact of CRRT and IHD on renal prognosis in elderly patients with AKI by analyzing their clinical data. Methods: The retrospective study population included elderly patients admitted to Xiangya Hospital between 2018 and 2022, who required RRT for AKI. Patients were separated into two cohorts based on the original RRT modes (CRRT or IHD). In our study, the primary outcome was recovery of renal function at discharge and the secondary outcome was RRT dependency rate at 90 days. A multivariate logistic regression model was constructed for the purpose of comparing the impact of CRRT and IHD on renal prognosis. Results: The mortality rate at the time of patient discharge was significantly elevated in the CRRT cohort relative to the IHD cohort (49.6% vs. 2.1%, p < 0.001). However, for the 155 patients who survived at discharge, the analysis revealed no statistically significant discrepancy in renal recovery across the two groups (40.3% vs. 59.7%, p = 0.694). Multivariate logistic regression analysis showed no statistically meaningful distinction among the CRRT and IHD groups concerning renal function recovery at discharge. Nevertheless, in comparison with IHD, CRRT reduced the risk of RRT dependence at 90 days. Conclusions: Our study indicated that CRRT and IHD have comparable effects on renal recovery at discharge in elderly patients with AKI who require RRT. However, in comparison with IHD, CRRT was linked to a diminished likelihood of requiring RRT at 90 days.
- 30 November 2023
- Published by Oxford University Press (OUP) in Stem Cells
- Vol. 42 (3) , 216-229
Application Potential of Extracellular Vesicles Derived From Mesenchymal Stem Cells in Renal Diseases
The high prevalence and complex etiology of renal diseases already impose a heavy disease burden on patients and society. In certain kidney diseases such as acute kidney injury and chronic kidney disease, current treatments are limited to slowing rather than stabilizing or reversing disease progression. Therefore, it is crucial to study the pathological mechanisms of kidney disease and discover new therapeutic targets and effective therapeutic drugs. As cell-free therapeutic strategies are continually being developed, extracellular vesicles derived from mesenchymal stem cells (MSC-EVs) have emerged as a hot topic for research in the field of renal diseases. Studies have demonstrated that MSC-EVs not only reproduce the therapeutic effects of MSCs but also localize to damaged kidney tissue. Compared to MSCs, MSC-EVs have several advantages, including ease of preservation, low immunogenicity, an inability to directly form tumors, and ease of artificial modification. Exploring the detailed mechanisms of MSC-EVs by developing standardized culture, isolation, purification, and drug delivery strategies will help facilitate their clinical application in kidney diseases. Here, we provide a comprehensive overview of studies about MSC-EVs in kidney diseases and discuss their limitations at the human nephrology level.
- 30 November 2023
- Published by Oxford University Press (OUP) in Stem Cells
- Vol. 42 (3) , 216-229
Application Potential of Extracellular Vesicles Derived From Mesenchymal Stem Cells in Renal Diseases
The high prevalence and complex etiology of renal diseases already impose a heavy disease burden on patients and society. In certain kidney diseases such as acute kidney injury and chronic kidney disease, current treatments are limited to slowing rather than stabilizing or reversing disease progression. Therefore, it is crucial to study the pathological mechanisms of kidney disease and discover new therapeutic targets and effective therapeutic drugs. As cell-free therapeutic strategies are continually being developed, extracellular vesicles derived from mesenchymal stem cells (MSC-EVs) have emerged as a hot topic for research in the field of renal diseases. Studies have demonstrated that MSC-EVs not only reproduce the therapeutic effects of MSCs but also localize to damaged kidney tissue. Compared to MSCs, MSC-EVs have several advantages, including ease of preservation, low immunogenicity, an inability to directly form tumors, and ease of artificial modification. Exploring the detailed mechanisms of MSC-EVs by developing standardized culture, isolation, purification, and drug delivery strategies will help facilitate their clinical application in kidney diseases. Here, we provide a comprehensive overview of studies about MSC-EVs in kidney diseases and discuss their limitations at the human nephrology level.
- Open Access
- 18 February 2022
- Published by Frontiers Media SA in Frontiers in Pharmacology
- Vol. 13, 840695
Hengli® Chinese Botulinum Toxin Type A for Treatment of Patients With Overactive Bladder: A Multicenter, Prospective, Randomized, Double-Blind, Placebo-Controlled Trial
Objective: To evaluate the efficacy and safety of Hengli® Chinese botulinum toxin type A (BTX-A; 100 U) in Chinese patients with overactive bladder.Methods: This study was a multicenter, randomized, double-blind, placebo-controlled trial in Chinese patients who were inadequately managed with anticholinergic medications. Eligible patients were randomized 2:1 to receive intradetrusor injections of Hengli® BTX-A (n = 144) or placebo (n = 72). The primary endpoint was the change in the number of daily micturition episodes at week 6 from baseline. The secondary efficacy endpoints included the average frequency of urgency and urinary incontinence (UI) episodes per day, urgency score, average micturition volume per day, OABSS, and QoL score.Results: In the Hengli® BTX-A group, there was a significantly greater reduction in the average number of micturition episodes per 24 h compared with the placebo group (3.28 vs. 1.43; p = 0.003). Moreover, there was a significantly greater improvement in the daily number of urgency episodes, micturition volume and OABSS score. An increased post-void residual urine volume, dysuria, and urinary tract infection represented adverse events (AEs) in the Hengli® BTX-A group. Most AEs were mild or moderate in severity. One patient in the BTX-A group initiated clean intermittent catheterization (CIC) during treatment.Conclusion: Hengli® BTX-A treatment was well-tolerated and resulted in significant improvements in OAB symptoms among Chinese patients inadequately managed by anticholinergics.Clinical Trial Registration:http://www.chinadrugtrials.org.cn/clinicaltrials.prosearch.dhtml, Identifier: CTR20131190.
- 18 February 2022
- Published by Frontiers Media SA in Frontiers in Pharmacology
- Vol. 13, 840695
Open AccessHengli® Chinese Botulinum Toxin Type A for Treatment of Patients With Overactive Bladder: A Multicenter, Prospective, Randomized, Double-Blind, Placebo-Controlled Trial
Objective: To evaluate the efficacy and safety of Hengli® Chinese botulinum toxin type A (BTX-A; 100 U) in Chinese patients with overactive bladder.Methods: This study was a multicenter, randomized, double-blind, placebo-controlled trial in Chinese patients who were inadequately managed with anticholinergic medications. Eligible patients were randomized 2:1 to receive intradetrusor injections of Hengli® BTX-A (n = 144) or placebo (n = 72). The primary endpoint was the change in the number of daily micturition episodes at week 6 from baseline. The secondary efficacy endpoints included the average frequency of urgency and urinary incontinence (UI) episodes per day, urgency score, average micturition volume per day, OABSS, and QoL score.Results: In the Hengli® BTX-A group, there was a significantly greater reduction in the average number of micturition episodes per 24 h compared with the placebo group (3.28 vs. 1.43; p = 0.003). Moreover, there was a significantly greater improvement in the daily number of urgency episodes, micturition volume and OABSS score. An increased post-void residual urine volume, dysuria, and urinary tract infection represented adverse events (AEs) in the Hengli® BTX-A group. Most AEs were mild or moderate in severity. One patient in the BTX-A group initiated clean intermittent catheterization (CIC) during treatment.Conclusion: Hengli® BTX-A treatment was well-tolerated and resulted in significant improvements in OAB symptoms among Chinese patients inadequately managed by anticholinergics.Clinical Trial Registration:http://www.chinadrugtrials.org.cn/clinicaltrials.prosearch.dhtml, Identifier: CTR20131190.